drugset
drugset / Trial / NCT05857332

SG1906 for CLDN18.2-Positive Solid Tumors

NCT05857332 ↗

Phase 1 Recruiting 60 enrolled Hangzhou Sumgen Biotech Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients with CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.

Timeline

Start
2023-05-30
Primary completion
2027-02-28
Completion
2027-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SG1906 Unknown 0.1 mg/kg Intravenous
Subject SG1906 Unknown 0.3 mg/kg Intravenous
Subject SG1906 Unknown 1 mg/kg Intravenous
Subject SG1906 Unknown 3 mg/kg Intravenous
Subject SG1906 Unknown 6 mg/kg Intravenous
Subject SG1906 Unknown 9 mg/kg Intravenous
Subject SG1906 Unknown 12 mg/kg Intravenous

Indications

cancer of unknown primary site